ENDLYZ THERAPEUTICS
ndLyz Therapeutics, Inc. is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias.
ENDLYZ THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2021-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Status:
Active
Total Funding:
3.25 M USD
Similar Organizations
Fiat Labs
Fiat Labs is currently operating in stealth mode.
Marlinspike Therapeutics
Marlinspike Therapeutics is a biotechnology company operating in stealth mode.
Route Line
Route Line is an end-to-end adventure company that provides access to beautifully outfitted, premium RVs, and Adventure vehicles.
Sanegene Bio
Sanegene Bio is currently operating in stealth mode.
More informations about "Endlyz Therapeutics"
EndLyz
Endlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease. Endlyz Therapeutics officially emerges from stealth, unveiling its therapeutic pipeline …See details»
Endlyz Therapeutics 2025 Company Profile: Valuation, …
Endlyz Therapeutics General Information Description. Developer of disease-modifying therapeutics based in Boston, USA. The company specializes in developing technology that restores endo-lysosomal function and abrogates …See details»
Endlyz Therapeutics - Crunchbase Company Profile
Endlyz Therapeutics closed its last funding round on Mar 31, 2025 from a Grant round. Who are Endlyz Therapeutics 's competitors? Alternatives and possible …See details»
EndLyz - Oxford Science Enterprises
EndLyz is an early stage biotech company developing disease-modifying therapeutics that restore endo-lysomsomal function to treat neurodegenerative disorders such as Parkinson’s Disease and other dementias. What Life …See details»
Endlyz Therapeutics - LinkedIn
Endlyz Therapeutics | 1,208 followers on LinkedIn. Developing therapeutics to restore endo-lysosomal function and halt neurodegeneration in Parkinson’s & other dementias. | Endlyz Therapeutics ...See details»
EndLyz Therapeutics - BIO International Convention 2025
Endlyz Therapeutics is a biotechnology company pioneering disease-modifying therapies that will restore lysosomal function and neuronal health in Parkinson’s disease and other …See details»
SV Health Investors Unveils Endlyz Therapeutics: A New …
Mar 31, 2025 Endlyz Therapeutics, recently launched by SV Health Investors, is poised to make significant strides in the realm of biopharmaceutical innovation, specifically targeting Parkinson’s disease. With the establishment of a …See details»
EndLyz Therapeutics - VentureRadar
Develops disease-modifying therapeutics to restore endo-lysosomal function for treating neurodegenerative disorders, including Parkinson's Disease and other dementias. EndLyz …See details»
Endlyz Therapeutics, Inc. in Boston, Massachusetts - EIN TaxId
Organization Name: Endlyz Therapeutics, Inc. IRS EIN (Taxpayer Id) 86-3243175: Type of business: Business Address and Contact Details: Business Phone: 617-945-4074: Business …See details»
Endlyz Therapeutics launches and unveils its portfolio of …
Mar 31, 2025 Endlyz is developing disease-modifying therapeutics to combat endo-lysosomal dysfunction, a key driver of neurodegeneration. Founded in 2021 by SV Health Investors’ …See details»
Endlyz Therapeutics | F6S
Similar companies Vilya Vivoryon Therapeutics Development of drugs for Alzheimer's disease Mineralys Therapeutics Bolt Biotherapeutics Elly Health Elly helps life science companies …See details»
Endlyz Therapeutics emerges with pipeline for Parkinson’s disease
Apr 7, 2025 Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators designed to restore lysosomal function in Parkinson’s disease (PD) and …See details»
Endlyz Therapeutics - Funding, Financials, Valuation & Investors
Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias. New. Resources. Advanced Search. Start Free Trial . ... How much …See details»
KU Leuven joins Endlyz Therapeutics’ fight against Parkinson's …
Apr 10, 2025 EndLyz Therapeutics, a UK-based biotech company, announces a collaboration with KU Leuven professor Peter Vangheluwe and the Center for Drug Design and Discovery …See details»
EndLyz Therapeutics | VentureRadar
EndLyz Therapeutics is developing disease-modifying therapeutics which restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease (PD) and other dementias. ...See details»
KU Leuven joins Endlyz Therapeutics’ fight against Parkinson's …
Apr 10, 2025 EndLyz Therapeutics, a UK-based biotech company, announces a collaboration with KU Leuven professor Peter Vangheluwe and the Center for Drug Design and Discovery …See details»
Endlyz Therapeutics - Crunchbase
Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias. New. Resources. Advanced Search. ... Experience the new Crunchbase, …See details»
News Archive | EndLyz
Mar 31, 2025 Endlyz Therapeutics officially emerges from stealth, unveiling its therapeutic pipeline of small molecule modulators targeting ATP13A2 and ATP10B to restore lysosomal …See details»
Endlyz Therapeutics - Updates, News, Events, Signals & Triggers
Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias. New. Resources. Advanced Search. ... Experience the new Crunchbase, …See details»
U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for …
May 14, 2025 "Despite the progress we have seen in the treatment of lung cancer, we need more options for people whose treatments stop working," said Upal Basu Roy, PhD, MPH, …See details»